Focused On-demand Library for Glutamate receptor ionotropic, delta-2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

O43424

UPID:

GRID2_HUMAN

Alternative names:

Alternative UPACC:

O43424; E9PH24; Q4KKU8; Q4KKU9; Q4KKV0; Q59FZ1

Background:

The Glutamate receptor ionotropic, delta-2 (GRID2) is pivotal in the central nervous system, acting as a receptor for glutamate, which is an excitatory neurotransmitter. It plays a crucial role in synaptogenesis and mediates long-term depression signals and AMPA receptor endocytosis in cerebellar synapses, essential for coordinated movement and cognitive processes.

Therapeutic significance:

GRID2's involvement in Spinocerebellar ataxia, autosomal recessive, 18, characterized by progressive cerebellar atrophy and intellectual disability, underscores its therapeutic potential. Targeting GRID2 could lead to novel treatments for this debilitating condition, offering hope for affected individuals.